Anktiva
What Anktiva is used for
Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Anktiva
- Active substance
- nogapendekin alfa inbakicept
- Disease area
- Non-Muscle Invasive Bladder Neoplasms
- Medicine group
- Immunostimulants
- ATC code
- L03AC03
- Marketing authorisation holder
- Immunitybio Ireland Limited
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Anktiva used for?
Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
What is the active substance in Anktiva?
Anktiva contains nogapendekin alfa inbakicept.
Who makes Anktiva?
The EU marketing authorisation holder is Immunitybio Ireland Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU